Brecanavir

Drugbox
IUPAC_name = [(3"R",3a"S",6a"R")-2,3,3a,4,5,6a-Hexahydrofuro [5,4-b] furan-3-yl] "N"- [(2"S",3"R")-4-(1,3-benzodioxol-5-ylsulfonyl-(2-methylpropyl)amino)-3-hydroxy-1- [4- [(2-methyl-1,3-thiazol-4-yl)methoxy] phenyl] butan-2-yl] carbamate

---

CAS_number = 313682-08-5
CAS_supplemental =
ATC_prefix =
ATC_suffix =
ATC_supplemental =
PubChem = 5743186
DrugBank =
chemical_formula =
C=33 | H=41 | N=3 | O=10 | S=2
molecular_weight = 703.82
bioavailability =
protein_bound =
metabolism =
elimination_half-life =
excretion =
pregnancy_AU =
pregnancy_US =
pregnancy_category=
legal_AU =
legal_CA =
legal_UK =
legal_US =
legal_status =
routes_of_administration =

Brecanavir (INN; codenamed "GW640385") is a protease inhibitor which has been studied for the treatment of HIV. [cite journal |author=Hazen R, Harvey R, Ferris R, "et al" |title=In vitro antiviral activity of the novel, tyrosyl-based human immunodeficiency virus (HIV) type 1 protease inhibitor brecanavir (GW640385) in combination with other antiretrovirals and against a panel of protease inhibitor-resistant HIV |journal=Antimicrob. Agents Chemother. |volume=51 |issue=9 |pages=3147–54 |year=2007 |month=September |pmid=17620375 |pmc=2043237 |doi=10.1128/AAC.00401-07 |url=]

On December 2006, its developer, GlaxoSmithKline discontinued further development because of insurmountable issues regarding formulation. [cite press release
title = GlaxoSmithKline discontinues clinical development of investigational protease inhibitor brecanavir (640385)
publisher = GlaxoSmithKline
date = 2006-12-18
url = http://www.gsk.com/media/pressreleases/2006/2006_12_18_GSK945.htm
accessdate = 2008-06-11]

References